Prognostic Correlation Study of MYO5A Exon 35 Skipping in Head and Neck Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2024.03.009

Abstract

Abstract: Objective: To explore the potential of MYO5A gene as a prognostic molecular marker in head and neck squamous cell carcinoma (HNSCC). Methods: RNA-Seq data and corresponding clinical data were downloaded from the TCGA database for the HNSCC queue, and the relationship between MYO5A and patient prognosis was analyzed using univariate Cox regression. The variable splicing types of the MYO5A gene were downloaded from the TCGA SpliceSeq database, the variable splicing of the differentially expressed MYO5A gene was identified based on the percentage spliced in (PSI) value, and its correlation with the prognosis of HNSCC patients was analyzed. Finally, RT-PCR and Sanger sequencing were validated in clinical samples from cell lines and affiliated hospitals of Xuzhou Medical University. Results: The MYO5A gene was significantly overexpressed in the HNSCC cohort, but the overall expression level of the MYO5A gene could not be used as an independent prognostic risk indicator for HNSCC. The frequency of MYO5A exon 35 hopping was increased in HNSCC and was closely related to prognosis. The jump of MYO5A exon 35 was validated in both cell lines and clinical samples. Conclusion: The jump of MYO5A exon 35 rather than the overall expression level of MYO5A gene can serve as an independent molecular marker for the prognosis of HNSCC.

Key words: MYO5A, head and neck squamous cell carcinoma, alternative splicing, prognosis

LU Fang, NING Tongtong, WANG Jie, ZHAO Jia, FANG Jing, NING Qianqian, LI Jiafeng. Prognostic Correlation Study of MYO5A Exon 35 Skipping in Head and Neck Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2024, 40(3): 236-241.

References

[1] Gormley M, Creaney G, Schache A, et al. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors [J]. Br Dent J, 2022, 233(9): 780-786.
[2] Kiong KL, De Souza NN, Sultana R, et al. Meta-analysis of induction chemotherapy as a selection marker for chemoradiation in the head and neck [J]. Laryngoscope, 2018, 128(7): 1594-1601.
[3] Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial [J]. Lancet Oncol, 2021, 22(4): 450-462.
[4] Sakai A, Ando M, Fukusumi T, et al. Aberrant expression of CPSF1 promotes head and neck squamous cell carcinoma via regulating alternative splicing [J]. PLoS One, 2020, 15(5): e0233380.
[5] Xing L, Zhang X, Tong D. Systematic profile analysis of prognostic alternative messenger RNA splicing signatures and splicing factors in head and neck squamous cell carcinoma [J]. DNA Cell Biol, 2019, 38(7): 627-638.
[6] Dolce LG, Silva-Junior RMP, Assis LHP, et al. Myosin Va interacts with the exosomal protein spermine synthase [J]. Biosci Rep, 2019, 39(3):BSR20182189.
[7] Huang K, Chen S, Xie R, et al. Identification of three predictors of gastric cancer progression and prognosis [J]. FEBS Open Bio, 2020, 10(9): 1891-1899.
[8] Chi H, Xie X, Yan Y, et al. Natural killer cell-related prognosis signature characterizes immune landscape and predicts prognosis of HNSCC [J]. Front Immunol, 2022, 13: 1018685.
[9] Zhang Y, Qian J, Gu C, et al. Alternative splicing and cancer: a systematic review [J]. Signal Transduct Target Ther, 2021, 6(1): 78.
[10] Xu W, Wang X, Wu X, et al. Prognostic value and underlying mechanism of KIAA0101 in hepatocellular carcinoma: database mining and co-expression analysis [J]. Aging (Albany NY), 2020, 12(16): 16420-16436.
[11] Cunningham F, Allen JE, Allen J, et al. Ensembl 2022 [J]. Nucleic Acids Res, 2022, 50(D1): D988-D995.
[12] Wong S, Weisman LS. Roles and regulation of myosin V interaction with cargo [J]. Adv Biol Regul, 2021, 79: 100787.
[13] Diaz-Valencia JD, Estrada-Abreo LA, Rodríguez-Cruz L, et al. Class Ⅰ Myosins, molecular motors involved in cell migration and cancer [J]. Cell Adh Migr, 2022, 16(1): 1-12.
[14] Carew JA, Cristofaro V, Dasari SP, et al. Myosin 5a in the urinary bladder: Localization, splice variant expression, and functional role in neurotransmission [J]. Front Physiol, 2022, 13: 890102.
[15] Shi DM, Dong SS, Zhou HX, et al. Genomic and transcriptomic profiling reveals key molecules in metastatic potentials and organ-tropisms of hepatocellular carcinoma [J]. Cell Signal, 2023, 104: 110565.
[16] Song D, Ye Z, Chen F, et al. circFNDC3B promotes esophageal squamous cell carcinoma progression by targeting MYO5A via miR-370-3p/miR-136-5p [J]. BMC Cancer, 2023, 23(1): 821.
[17] Zhu Y, Zheng S, Zhai X, et al. Comprehensive landscape of prognostic significance and immune characteristics of myosins in squamous cell carcinoma of the head and neck [J]. J Immunol Res, 2022, 2022: 5501476.
[18] Sneeggen M, Guadagno NA, Progida C. Intracellular transport in cancer metabolic reprogramming [J]. Front Cell Dev Biol, 2020, 8: 597608.
[19] Engevik KA, Engevik MA, Engevik AC. Bioinformatics reveal elevated levels of Myosin Vb in uterine corpus endometrial carcinoma patients which correlates to increased cell metabolism and poor prognosis [J]. PLoS One, 2023, 18(1): e0280428.
[20] Kravtsov D, Mashukova A, Forteza R, et al. Myosin 5b loss of function leads to defects in polarized signaling: implication for microvillus inclusion disease pathogenesis and treatment [J]. Am J Physiol Gastrointest Liver Physiol, 2014, 307(10): G992-G1001.